fda compounding semaglutide news today 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 What Patients Need to Know
Description
Tirzepatide is not appropriate for individuals with a history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis, or certain endocrine conditions
In clinical trials studying Wegovy (2.4 mg), the average weight loss was 15% and 20%, respectively, when paired with diet and exercise (compared to 2.4% and 3.1% with diet and exercise alone)
This dryness can intensify the Wegovy taste in mouth, leaving a coated, metallic, or slightly bitter sensation throughout the day
Prokinetics in patients with gastroparesis: a systematic analysis
NCT02128932
Is there a long-term affordability plan
